FAQ: Izotropic Corporation's IzoView Breast CT Platform Commercialization Strategy
Summary
Izotropic Corporation CEO Bob Thast discussed the company's commercialization strategy for the IzoView breast CT platform in a new Departures Capital interview, highlighting imaging advantages, patient benefits, and near-term capital deployment plans including FDA clinical studies and CE-mark activities.
What is Izotropic Corporation and what does it develop?
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) is a medical device company commercializing innovative imaging technologies and products for more accurate screening, diagnosis, and treatment of breast cancers, with its flagship IzoView breast CT platform.
What was announced in the recent press release?
Izotropic announced the release of a new video interview with CEO Bob Thast in partnership with Departures Capital, discussing the company’s vision and near-term strategy for the IzoView breast CT platform, including imaging advantages, patient benefits, and market differentiation.
What are Izotropic’s near-term capital deployment plans?
Over the next 12-18 months, Izotropic plans to produce three IzoView units for an upcoming U.S. FDA clinical study, a partner device in the U.K. to support CE-mark activities, and two additional systems targeting CE-mark-accepted markets to accelerate regulatory approvals and commercialization.
Where can I watch the full CEO interview?
The full press release with details about the CEO interview can be viewed at https://ibn.fm/hTAhP.
What regulatory approvals is Izotropic pursuing for IzoView?
Izotropic is pursuing U.S. FDA approval through clinical studies and CE-mark acceptance for European markets, with plans for systems in the U.K. and other CE-mark-accepted markets to accelerate regulatory approvals.
Who is the CEO of Izotropic Corporation?
Bob Thast is the CEO of Izotropic Corporation, who discussed the company’s commercialization strategy and vision for the IzoView breast CT platform in the Departures Capital interview.
Where can investors find the latest news about Izotropic?
The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF.
What is TechMediaWire and what services do they provide?
TechMediaWire is a specialized communications platform within IBN’s Dynamic Brand Portfolio that provides wire solutions, article syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions for technology companies.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 262416